Covid self-testing kit to be available in 3-4 days: ICMR

DY365
DY365
Published: May 20,2021 09:30 PM
DY365

Story highlights

At-home COVID-19 tests should be available in the market in the next three to four days, the Indian Council of Medical Research (ICMR) said on Thursday.

May 20, 2021: At-home COVID-19 tests should be available in the market in the next three to four days, the Indian Council of Medical Research (ICMR) said on Thursday.



While speaking at a press briefing in Delhi, Dr Balram Bhargava, Director General of the ICMR informed that results for home COVID testing will be processed and delivered through a mobile application.



"Step 1 is that you buy the test kit from a chemist, Step 2 - download the mobile app. Step 3- conduct the test at home. Step 4 - click a mobile image and upload. The test result will be given," Bhargava explained.



He added, "This ensures patient confidentiality, data is stored in a secure server and it is linked with the ICMR database. This should be available in the market within three to four days. One company has approval for home testing kits, three more are in the pipeline."



Earlier on Thursday, Pune's Mylab Discovery Solutions launched India's first-ever self-testing kit for COVID-19, which has received the approval of the Indian Council of Medical Research (ICMR).



The ICMR DG further said that over 20 lakh tests were conducted on May 18 and 19 across the country, the highest ever figures. Despite this, the positivity rate has dropped to about 13 per cent.



"In the middle of February till early March, we were doing about 8 lakh tests per day and have increased that to 20 lakh. Yet our positivity percentage has fallen to 13 per cent from 28 per cent. We have to bring it down to 5 per cent," he said.



He added that they aim to do 25 lakh tests per day by the end of this month and 45 lakh tests by the end of June



"More Rapid Antigen Tests should be done because you can get results rapidly and then isolate the patient quickly," he added.



Bhargava further said that the Defence Research and Development Organisation's 2-DG drug is not a new medicine and has been repurposed.



"The DRDO's 2-DG drug is a repurposed medicine, not a new medicine. It was earlier used for cancer treatment. Its trial results have been given to DCGI," the said.